International journal of radiation oncology, biology, physics · 2025
Proton Beam Therapy for Intrahepatic and Perihilar Cholangiocarcinoma: A Multicenter Prospective Registry Study: Potential Candidates for High-Dose Proton Beam Therapy.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamazaki Hideya, Shibuya Kei, Kimoto Takuya, Suzuki Motohisa, Murakami Masao, Terashima Kazuki, Okimoto Tomoaki, Iizumi Takashi, Sakurai Hideyuki, Wakatsuki Masaru, Ogino Takashi, Arimura Takeshi, Takagi Masaru, Araya Masayuki, Waki Takahiro, Matsumoto Sae, Ogino Hiroyuki, Katoh Norio, Hashimoto Takayuki, Hojo Hidehiro, Fukumitsu Nobuyoshi, Murayama Shigeyuki
Аннотация
PURPOSE: Because dose escalation radiation therapy can improve local control (LC), stereotactic body radiation therapy has achieved better results than conventional radiation therapy in liver malignancies. This study aimed to investigate the role of dose escalation proton beam therapy (PT) in patients with intrahepatic cholangiocarcinoma (iCCA) and perihilar cholangiocarcinoma (pCCA).
METHODS AND MATERIALS: We analyzed data from a multi-institutional prospective registry that included all Japanese proton beam facilities between May 2016 and May 2021. Endpoints were LC, progression-free survival, overall survival (OS), and toxicity.
RESULTS: We included 236 patients with unresectable cholangiocarcinoma (133 iCCA and 103 pCCA) treated with PT with a median prescribed dose of 72.6 Gy (RBE) (range, 50-76 Gy Relative Biological Effectiveness (RBE)) in 25 fractions (range, 10-38 fractions). With a median follow-up of 20.0 months for surviving patients, the median OS was 19 months, and the 2-year OS was 44.8%. For iCCA and pCCA, the median OSs were 17 and 20 months, respectively. Two-year progression-free survival and LC rates were 20.6% and 66.5%, respectively. Multivariable analyses revealed that liver function and the distance between the tumor and the gastrointestinal tract were significantly associated with OS, whereas the overall treatment time was associated with LC. Furthermore, liver function and tumor diameter were associated with progression-free survival. The median OS for patients with gastrointestinal distance ≥2 cm and a higher prescribed dose (≥74 Gy in equivalent 2-Gy fractions) was 37 months (2-year OS 61.8%), compared with 18.0 months (33.1%) for other patients (P< .001). Twenty-one patients experienced adverse reactions of grade 3 or higher (8.9%).
CONCLUSIONS: PT showed good efficacy with acceptable toxicity for unresectable iCCA and pCCA without distant metastasis. Especially in patients with gastrointestinal distance ≥2 cm, high-dose PT was associated with improved OS.
METHODS AND MATERIALS: We analyzed data from a multi-institutional prospective registry that included all Japanese proton beam facilities between May 2016 and May 2021. Endpoints were LC, progression-free survival, overall survival (OS), and toxicity.
RESULTS: We included 236 patients with unresectable cholangiocarcinoma (133 iCCA and 103 pCCA) treated with PT with a median prescribed dose of 72.6 Gy (RBE) (range, 50-76 Gy Relative Biological Effectiveness (RBE)) in 25 fractions (range, 10-38 fractions). With a median follow-up of 20.0 months for surviving patients, the median OS was 19 months, and the 2-year OS was 44.8%. For iCCA and pCCA, the median OSs were 17 and 20 months, respectively. Two-year progression-free survival and LC rates were 20.6% and 66.5%, respectively. Multivariable analyses revealed that liver function and the distance between the tumor and the gastrointestinal tract were significantly associated with OS, whereas the overall treatment time was associated with LC. Furthermore, liver function and tumor diameter were associated with progression-free survival. The median OS for patients with gastrointestinal distance ≥2 cm and a higher prescribed dose (≥74 Gy in equivalent 2-Gy fractions) was 37 months (2-year OS 61.8%), compared with 18.0 months (33.1%) for other patients (P< .001). Twenty-one patients experienced adverse reactions of grade 3 or higher (8.9%).
CONCLUSIONS: PT showed good efficacy with acceptable toxicity for unresectable iCCA and pCCA without distant metastasis. Especially in patients with gastrointestinal distance ≥2 cm, high-dose PT was associated with improved OS.